Wang Y, Wang L, Saxena R, et al. Clinicopathological Features of He Shou Wu-induced Liver Injury. Liver Int 2019 Feb;39(2):389-400.
+++++
Liver Int. 2019 Feb;39(2):389-400. doi: 10.1111/liv.13939. Epub 2018 Aug 25.
Clinicopathological features of He Shou Wu-induced liver injury: This ancient anti-aging therapy is not liver-friendly.
Wang Y1, Wang L1, Saxena R2, Wee A3, Yang R1, Tian Q1, Zhang J4, Zhao X1, Jia J1
Abstract
BACKGROUND & AIMS:
Polygonum Multiflorum Thumb (PMT), an ancient anti-aging Chinese herb known traditionally as He Shou Wu, has side effects of liver toxicity. To determine the main clinical and pathological characteristics of liver toxicity induced by PMT and the clinical course after its cessation.
METHODS:
Data of patients, diagnosed as drug-induced liver injury and hospitalised in Beijing Friendship Hospital from August 2005 to August 2017, were retrospectively reviewed. Clinical, pathological data and outcome after cessation of He Shou Wu were obtained and analysed. Kruskal-Wallis and Chi-square (χ2 ) tests were performed.
RESULTS:
Twenty-nine patients with He Shou Wu-induced liver injury were enrolled. The median age was 53 years (range 15-74) and 75.9% (22/29) were women. The most common symptom was jaundice (79.3%, 23/29). Of nine patients with liver biopsies, six showed acute cholestatic hepatitis, two acute, and one chronic hepatocellular injury pattern. The latency, liver chemistries and outcomes were comparable between pure He Shou Wu (5 patients) and its compounds (24 patients). Twenty-five of 29 patients (86.2%) had normal serum alanine aminotransferase levels after 45 days (range: 10-138 days) and total bilirubin of 46 days (range: 0-551 days). One patient was rechallenged with He Shou Wu and two developed autoimmune features. One patient died of liver failure and three had chronic persistent liver injury.
CONCLUSIONS:
The main clinicopathological injury pattern of He Shou Wu-induced liver injury is moderate to severe hepatitis with or without cholestasis. Most patients recover completely; however, chronic disease and death do occur.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
1. Integrating Telemedicine and Remote Care: As the Typical Collaborating Physician Pay increasingly reflects their adaptability to new technologies, collaborating physicians and medical directors in IV Hydration are incorporating telemedicine into their services.
2. Enhancing Patient-Centered Care: For medical directors in IV Hydration, this means tailoring treatments to individual patient needs, a skill increasingly valued and reflected in the medical director for IV Hydration pay scale. The ability to customize care enhances patient outcomes and thus becomes a key component in evaluating performance-based incentives in their compensation.
3. Leadership in Multidisciplinary Teams: Leading multidisciplinary teams is becoming more significant in defining the typical collaborating physician pay.
4. Research and Innovation: By contributing to advancements in IV hydration therapy, these professionals are seeing a corresponding increase in their value and compensation as they bring new insights and efficiencies to patient care.
5. Regulatory Compliance and Quality Assurance: Being a Medical Director for IV Hydration requires expertise and diligence, which is increasingly factored into the compensation models for these positions. Maintaining high standards for IV hydration services is critical in determining their financial rewards.